Lopinavir / Ritonavir
Sponsors
Oswaldo Cruz Foundation, Kirby Institute, AbbVie (prior sponsor, Abbott), UMC Utrecht, Food and Drug Administration (FDA)
Conditions
COVID-19Community-acquired Pneumonia, Influenza, COVID-19Covid19Drug-induced QT ProlongationFavipiravirHIVHIV InfectionsHigh-Grade Anal Intraepithelial Neoplasia
Phase 1
CiPA Phase 1 ECG Biomarker Validation Study
CompletedNCT03070470
Start: 2017-03-14End: 2017-06-26Updated: 2020-01-18
Lopinavir/Ritonavir in PLWH With High-Grade AIN
RecruitingNCT05334004
Start: 2023-12-19End: 2026-06-01Target: 21Updated: 2026-02-10
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
RecruitingNCT05925140
Start: 2020-03-28End: 2025-12-30Target: 1000Updated: 2024-02-06
Phase 2
Phase 3
Phase 4
Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy
CompletedNCT00605098
Start: 2008-02-29End: 2012-07-31Updated: 2013-10-28
Bone and Body Comp: A Sub Study of the SECOND-LINE Study
CompletedNCT01513122
Start: 2010-02-28End: 2013-08-31Updated: 2025-06-26
Umifenovir in Hospitalized COVID-19 Patients
NCT04350684
Start: 2020-04-15End: 2020-04-24Target: 40Updated: 2020-04-20
Interferon Beta 1a in Hospitalized COVID-19 Patients
NCT04350671
Start: 2020-04-15End: 2020-04-24Target: 40Updated: 2020-04-20
Unknown Phase
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
CompletedNCT01662336
Start: 2012-06-30End: 2016-06-30Updated: 2018-01-29
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
CompletedNCT04376814
Start: 2020-03-29End: 2020-05-25Updated: 2020-06-16
Public Health Emergency: SOLIDARITY TRIAL Philippines
CompletedNCT05024006
Start: 2020-04-23End: 2021-04-17Updated: 2022-03-02
Related Papers
12 more papers not shown